Painless? My Assets

Recs

0

Just when you think the pain for Merck (NYSE: MRK) shareholders is about as bad as it can get for biotechs, along comes the sting for tiny Biolase Technology (Nasdaq: BLTI). The firm, which makes tissue-cutting laser systems for use in dental surgery, is down 14% today after dropping guidance for the upcoming quarters.

The story is familiar to denizens of the Hidden Gems boards, as the company's cutting-edge technology, diminutive market cap, growth potential, and undersized institutional holdings made it a candidate worthy of further study. Were we looking at a future Transkaryotic (Nasdaq: TKTX) or TransAct (Nasdaq: TACT), or would this be a heartbreaker like eSpeed (Nasdaq: ESPD)?

Unfortunately for shareholders, it's been the latter. A series of warnings coupled with investor suspicions about inventory and accounting have pushed the stock down about 60% to near a 52-week low. A couple of pretty sharp Fool contributors have sliced and diced the previous numbers here and here.

Third-quarter revenues are now expected to come in somewhere around $12 million, but that won't be enough to keep the company in the black. Though the company claimed that this quarter's sales drop was due to hurricanes and buyers holding out for a newer Biolase model, it also lowered the fourth-quarter's revenue target. If you ask me, I'd expect the deferred sales would push up the next quarter's results, but well, no one asked me.

I'm a great lover of damaged goods, but this stock doesn't make my list. If you feel differently, you might at least wait until management has something more tangible to offer shareholders than apologies and a token dividend.

For related Foolishness:

Seth Jayson spent a good deal of time working in his father's dental practice, where a Biolase system is not on the wish list. At the time of publication, he had positions in no company mentioned. View his stock holdings and Fool profile here. Fool rules are here.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 502313, ~/articles/articlehandler.aspx, 12/4/2008 8:18:48 PM,

Sign up for FREE Motley Fool site access to keep reading:

“Painless? My Assets”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recent

Most Recommended

Market Summary

S&P 500845.22 -2.93%
DJIA8,376.24 -2.51%
NASD1,445.56 -3.14%
Updated: 4:02:39 PM
Sponsored by:

Related Tickers

Biolase Technology, Inc.

CAPS Rating 1/5 Stars

$0.93

-0.07 (-7.00%)

Outperform39

Underperform14

Rate This Stock